Anatomy explorers have charted a new path myeloid cells use to access the brain. On 3 June in Neuron, scientists led by Lindsay Hohsfield and Kim Green, both at the University of California, Irvine, ...

The study started a year ago. Since then, more than 7,000 people who saw the website or pamphlets at their doctors’ offices signed up. Of these, just under 5,000 completed initial cognitive testing ...

Meanwhile, new findings from cell and animal models continued to paint a kaleidoscopic picture of TREM2 function. For example, microglia making the most TREM2—the ones scientists hope to energize with ...

Their analysis of three large population studies found that age-adjusted prevalence has dropped by a whopping two-thirds over the last 40 years. In other words, every successive birth cohort has a ...

These studies led the authors to investigate whether xenon could ameliorate Alzheimer’s disease. Because Butovsky’s lab studies microglia, which carry most of the genetic risk for AD, they looked to ...

The advisory committee voted 11 to 0 on both questions in favor of the approval of donanemab. The committee recognized, correctly I think, that the data supported a modestly favorable benefit to risk ...

For decades, the U.S. Food and Drug Administration has taken a light touch to regulating diagnostic tests that use body fluids or tissues. Such assays, very much including cerebrospinal fluid and ...

While the range of therapeutic approaches is broad, several sessions kept a spotlight on amyloid immunotherapy. Here, the buzziest data came from Roche, which reported that at the highest dose yet ...

In the hunt for blood biomarkers that predict dementia risk, a large proteomics study has flushed out quarry both old and new. Researchers led by Jin-Tai Yu, Wei Cheng, and Jian-Feng Feng at Fudan ...

The DIAN study follows hundreds of families with inherited AD. The cohort includes people who carry presenilin and APP mutations, as well as their unaffected relatives. Previous studies in this cohort ...

Not so long ago, a blood test for Alzheimer’s disease seemed a pipe dream. Now, after years of study, the field is awash with sensitive assays that signal the proteopathic culprits Aβ and tau ...

Yadong Huang and colleagues at the University of California, San Francisco, saw that the Christchurch variant can also protect against pathology driven by ApoE4. In the November 13 Nature Neuroscience ...